Poteligeo mogamulizumab: Preliminary Phase II data

Preliminary data from an open-label, international Phase II trial in 71 patients with relapsed or refractory ATL showed that 1

Read the full 200 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE